VialTalk's catalog lists this blend as "Amylin Agonist + Triple Agonist". Its vendor listing is "Eloralintide + PL-RT Blend", and in the catalog PL-RT is an alias of the Triple Agonist entry, which is retatrutide. The blend therefore pairs two investigational Eli Lilly peptides: eloralintide, a selective amylin receptor agonist, and retatrutide, a single molecule that activates the GIP, GLP-1 and glucagon receptors. This monograph sets out what each component contributes and how far the evidence goes. No study of this exact pairing has been published.
Composition
| Component | Catalog entry | Class | Status |
|---|
| Eloralintide (LY3841136) | Amylin Agonist | Selective amylin (AMY1R-preferring) receptor agonist | Investigational; Phase 3 registered [10] |
| Retatrutide (LY3437943) | Triple Agonist (alias PL-RT) | GIP / GLP-1 / glucagon receptor triple agonist | Investigational; not approved [1] |
Vendor listings give a combined fill amount, but the ratio of the two components inside the vial is not established in the catalog data. Check the COA for both identities and for each one's content. This monograph does not discuss ratios.
What each component contributes
Eloralintide: the amylin pathway.
- Amylin slows gastric emptying, suppresses glucagon and promotes satiation through the brain. This route is separate from the incretin receptors [6].
- In cell assays, eloralintide activated the human AMY1R about 12-fold more than the calcitonin receptor and 11-fold more than AMY3R [2].
- In rats it caused less conditioned taste avoidance than the non-selective agonist cagrilintide [2].
- In a 48-week Phase 2 trial in 263 adults, mean weight change was about −9% to −20% across the eloralintide arms, compared with −0.4% on placebo. Nausea and fatigue were the most common adverse events [3].
Retatrutide: the incretin and glucagon pathways.
- Retatrutide activates the GIP, GLP-1 and glucagon receptors [4][5].
- The added glucagon-receptor activity is thought to raise energy expenditure. It is the least-characterised part of the molecule [1].
- In a 48-week Phase 2 trial in 338 adults, mean weight change at 48 weeks was between −8.7% and −24.2% across the retatrutide groups, compared with −2.1% on placebo [4].
- Gastrointestinal adverse events were the most common and became more common at higher exposure. Heart rate rose with higher exposure, peaked at 24 weeks and then declined [4].
- Its long-term safety, particularly for the glucagon arm, is not yet characterised [1].
Why researchers pair the two pathways. One review describes amylin-based agents as acting through actions complementary to GLP-1-based agents [5]. Another describes the amylin pathway as acting through distinct neuroendocrine circuits [9]. That is the reasoning behind studying the two together. It is a hypothesis, not a demonstrated result for this pair.
Combination evidence — the honest boundary
- Human: none for this pairing. A PubMed search for eloralintide together with retatrutide found only a narrative review that names both drugs separately [9]. We found no trial, case series or pharmacokinetic study giving the two together. No human data exist on their combined safety, tolerability, interactions or efficacy.
- Closest human design (no results yet). A registered Phase 3 study is testing eloralintide against placebo in people with persistent obesity who are already on stable weekly incretin therapy [10]. The registry entry does not say that retatrutide is that background therapy. The study is recruiting and has reported no results.
- Animal: related pairings only.
- Eloralintide combined with tirzepatide, a dual GIP/GLP-1 agonist and not retatrutide, reduced food intake, body weight and fat mass in diet-induced obese rats more than either drug alone. This is a Lilly-authored conference abstract [7].
- In diet-induced obese male rats, cagrilintide combined with retatrutide reduced body weight and food intake more than either drug alone. It also beat comparator combinations that used semaglutide or tirzepatide at matched exposure, and it improved cholesterol, triglycerides and insulin [8]. Cagrilintide, however, is an amylin/calcitonin receptor co-agonist and not eloralintide [2][8]. Given the difference in receptor selectivity [2], this result cannot be assumed to transfer.
- Overlapping adverse effects are a known unknown. Both components on their own produced gastrointestinal adverse events in Phase 2 [3][4]. Whether combining them adds to, offsets or compounds those effects has not been studied.
- Formulation is uncharacterised. We found no published data on whether the two peptides are compatible or stable when co-formulated in a single lyophilized vial.
Research context
The two components are separate investigational products from the same sponsor. Neither is approved [1]; eloralintide is described as in development [3]. Combining amylin and incretin pathways is an active research direction, mainly through cagrilintide-based combinations and single-molecule co-agonists [5][9]. Researchers looking at this blend are working at the edge of that direction, without direct evidence. Any claim that the blend "works better" than either component goes beyond the published data.
Storage and handling
Research-grade material is supplied as a lyophilized powder. Keep sealed vials cold, dry and protected from light, and follow the batch COA or label. No stability data for this two-peptide co-formulation were found. This monograph does not cover preparation.
Quality and COA considerations
A two-peptide vial needs more verification than a single compound:
- the COA should confirm the identity of both eloralintide and retatrutide, ideally by LC-MS with resolved peaks
- it should report purity by HPLC
- it should state each component's content, not just a total fill
A single purity figure for the whole vial cannot show whether either component is missing, degraded or substituted. Because both catalog labels are generic class names, check that the COA names the specific molecules.
Key references
- VialTalk monograph — Retatrutide (Triple Agonist) — https://vialtalk.com/forum/peptide-research-library/retatrutide-research-monograph-triple-agonist-phase2
- Briere et al., Mol Metab 2025 — Eloralintide discovery to clinical proof of concept — https://pubmed.ncbi.nlm.nih.gov/41109426/
- Billings et al., Lancet 2025 — Eloralintide 48-week Phase 2 RCT — https://pubmed.ncbi.nlm.nih.gov/41207310/
- Jastreboff et al., N Engl J Med 2023 — Retatrutide Phase 2 for obesity — https://pubmed.ncbi.nlm.nih.gov/37366315/
- Son et al., Endocr Rev 2026 — Novel GLP-1-based medications (review) — https://pubmed.ncbi.nlm.nih.gov/41054801/
- Fischer & Borner, Pharmacol Res 2026 — Amylin pharmacotherapy and tolerability (review) — https://pubmed.ncbi.nlm.nih.gov/42586227/
- Briere et al., ADA abstract 3082-LB — Eloralintide + tirzepatide in DIO rats — https://www.semanticscholar.org/paper/72bed0c5b0ba7ae26fc01d6b531400882147479a
- Petersen et al., Nat Metab 2026 — Cagrilintide + retatrutide in obese rats — https://pubmed.ncbi.nlm.nih.gov/42744908/
- Lempesis & Dalamaga, Metabol Open 2026 — Multi-receptor agonists (review) — https://pubmed.ncbi.nlm.nih.gov/41948476/
- ClinicalTrials.gov NCT07392190 — Eloralintide on stable incretin background — https://clinicaltrials.gov/study/NCT07392190
Research-use note: This is an educational summary of published research. Both components are investigational and not approved, and their combination has not been studied in humans. This is research context only, not medical advice, and it contains no usage guidance.
